A randomized, double-blind, placebo-controlled trial evaluating the safety of ipilimumab (CA184-029), a CTLA-4 inhibitor, in adjuvant treatment of melanoma found a severe to fatal myocarditis incidence of 0.2%5. The gene discussed is CTLA4; the disease is myocarditis.